Drugs / CANOSIMIBE
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00440154 | Feb → Oct 2007 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT00766688 | Oct 2008 → Apr 2009 | hyperlipidemia | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT00741715 | Aug 2008 → May 2009 | hyperlipidemia | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT00729027 | Jul 2008 → Jun 2009 | hyperlipidemia | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT00718965 | Jul → Nov 2008 | hyperlipidemia | Sanofi | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CANOSIMIBE | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068542 ↗ |
| Known as | AVE5530 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00766688 ↗ |
| Modality | Small molecule | — CHEMBL6068542 ↗ |
| Route | Oral | “oral administration 5 mg breakfast timing” NCT00440154 ↗ |